Market Research

Psychedelic Invest is your source for the latest business and investing news about the burgeoning psychedelics industry.

Contemplating a psychedelic “trip”? Here is all you need to know about two of your options: Psilocybin vs. DMT

Jul 22 • 11 min read

As the psychedelic revolution becomes more socially accepted, academically acknowledged, and scientifically backed, many questions loom regarding the hierarchy of psychedelic substances. The plethora of research, profusion of media coverage, and growing flood of anecdotes demonstrate that substances such as ayahuasca, DMT, psilocybin, MDMA, and LSD have groundbreaking healing potential. It has become evident that…

Research is the Emerging Psychedelics Framework

Jul 9 • 3 min read

While psychedelic legalization and decriminalization across the United States is becoming more prevalent, there is a new emerging psychedelic framework: research. Texas has passed legislation that commits to studying psychedelics, in addition to Connecticut and New York. Under a psychedelic research framework, the state commits to conducting formal studies to research the efficacy of using…

Psychedelic Invest Adds 8 New Companies to its Index

Jul 1 • 4 min read

We are excited to add 8 new companies to our Psychedelic Invest Index – the first index in the market that comprehensively covers the entire public psychedelic sector. Nearly one year ago, we launched this index to bring much-needed financial data for new investors tracking the market. At the time, the index only consisted of…

Psychedelic Drugs: Is “Tripping” Necessary to Reap Their Benefits?

Jul 1 • 7 min read

The prevailing narrative surrounding psychedelic drug use depends on the out-of-body, out-of-mind experience that most believe is inevitable. When individuals confront the idea of a psychedelic experience, they typically imagine a completely altered state of consciousness including: Potent visuals. From bright luminous colors to complex geometric patterns to astonishing environmental transformations, the images that come…

psychedelic legalization vs decriminalization

Understanding Legalization v. Decriminalization in the Psychedelics Industry

Jun 28 • 6 min read

A variety of psychedelic substances, such as psilocybin, ketamine, MDMA, LSD, among others are gaining traction as an effective treatment for a variety of conditions. With ketamine classified as a Schedule III controlled substance and other psychedelic substances progressing through the FDA approval process, several states and municipalities have enacted psychedelic legalization and decriminalization measures. …

Pages: 1234567891011121314151617181920212223242526272829303132333435363738394041424344454647484950515253